Stock Events

Stock Events

Phathom Pharmaceuticals 

$11.02
0
-$0.11-0.99% Friday 06:26

Statistics

Day High
11.04
Day Low
11.02
52W High
-
52W Low
-
Volume
4,530
Avg. Volume
-
Mkt Cap
783.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2025
Q4 2025
Next
-0.46
-0.4
-0.33
-0.27
Expected EPS
-0.2687
Actual EPS
N/A

Financials

-605.09%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
110.5MRevenue
-668.65MNet Income

Analyst Ratings

$23.00Average Price Target
The highest estimate is 26.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHAT.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Takeda Pharmaceutical
TAK
Mkt Cap42.62B
Takeda Pharmaceutical Company has a strong portfolio in gastroenterology, competing in the same space as Phathom Pharmaceuticals.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca produces gastrointestinal drugs that directly compete with Phathom's offerings.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, having acquired Allergan, competes in the gastrointestinal drug market, overlapping with Phathom's therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, offers products that compete in the gastrointestinal sector.
Sanofi
SNY
Mkt Cap124.45B
Sanofi has a presence in the gastroenterology market, making it a competitor to Phathom Pharmaceuticals.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse range of products, including treatments for gastrointestinal disorders, competing with Phathom.
Novartis
NVS
Mkt Cap237.61B
Novartis offers medications for a variety of conditions, including gastrointestinal diseases, competing with Phathom Pharmaceuticals.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. provides therapeutic solutions in various areas, including gastroenterology, making it a competitor.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a portfolio of medicines that includes treatments for acid-related conditions, competing with Phathom Pharmaceuticals.

About

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Show more...
CEO
ISIN
US71722W1071

Listings

XNAS
US
PHAT
BOATS
BOATS
PHAT.BOATS

0 Comments

Share your thoughts

FAQ

What is Phathom Pharmaceuticals stock price today?▼
The current price of PHAT.BOATS is $11.02 USD — it has decreased by -0.99% in the past 24 hours. Watch Phathom Pharmaceuticals stock price performance more closely on the chart.
What is Phathom Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Phathom Pharmaceuticals stocks are traded under the ticker PHAT.BOATS.
What is Phathom Pharmaceuticals market cap?▼
Today Phathom Pharmaceuticals has the market capitalization of 783.94M
When is the next Phathom Pharmaceuticals earnings date?▼
Phathom Pharmaceuticals is going to release the next earnings report on May 12, 2026.
What were Phathom Pharmaceuticals earnings last quarter?▼
PHAT.BOATS earnings for the last quarter are -0.29 USD per share, whereas the estimation was -0.41 USD resulting in a +29.61% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Phathom Pharmaceuticals revenue for the last year?▼
Phathom Pharmaceuticals revenue for the last year amounts to 110.5M USD.
What is Phathom Pharmaceuticals net income for the last year?▼
PHAT.BOATS net income for the last year is -668.65M USD.
When did Phathom Pharmaceuticals complete a stock split?▼
Phathom Pharmaceuticals has not had any recent stock splits.